[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337375-105":59,"doc-detail-337375-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","quantifying-the-expanding-landscape-of-clinical-actionability-for-patients-with-cancer","Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer","","There is an ongoing debate about how many cancer patients benefit from precision oncology, largely due to disagreements over which molecular alterations are clinically actionable. To measure how this has changed since 2017, the study annotated 47,271 solid tumors sequenced with the MSK-IMPACT clinical assay using two OncoKB knowledge-base versions deployed five years apart. From 2017 to 2022, actionability increased (8.9% to 31.6%), while nonactionable drivers nearly halved (44.2% to 22.8%).",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/quantifying-the-expanding-landscape-of-clinical-actionability-for-patients-with-cancer/337375/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/quantifying-the-expanding-landscape-of-clinical-actionability-for-patients-with-cancer/337375.png","ImageObject",300,407,{"name":92,"@type":93},"Jiven","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How did the study quantify changes in clinical actionability from 2017 to 2022?","Question",{"text":112,"@type":113},"It annotated 47,271 solid tumors sequenced with the MSK-IMPACT assay using two OncoKB versions deployed five years apart.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What overall trends were observed in actionable and nonactionable tumors?",{"text":117,"@type":113},"The fraction with standard care predictive biomarkers increased from 8.9% to 31.6%, while tumors with nonactionable drivers dropped from 44.2% to 22.8%.",{"name":119,"@type":110,"acceptedAnswer":120},"Which genes were most frequently altered in tumors with limited or no clinical actionability?",{"text":121,"@type":113},"TP53 (43.2%), KRAS (19.2%), and CDKN2A (12.2%) were the most frequently altered genes.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},337375,1790284249,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","RESEARCH BRIEF  \nQuantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer   \nSarah P. Suehnholz1,2, Moriah H. Nissan1,2, Hongxin Zhang1, Ritika Kundra1, Subhiksha Nandakumar1, Calvin Lu1, Stephanie Carrero1, Amanda Dhaneshwar1,2, Nicole Fernandez1,2, Benjamin W. Xu3,  \nMaria E. Arcila2, Ahmet Zehir2, Aijazuddin Syed2, A. Rose Brannon2, Julia E. Rudolph1, Eder Paraiso1, Paul J. Sabbatini4, Ross L. Levine4,5, Ahmet Dogan2, Jianjiong Gao1,6, Marc Ladanyi2,5, Alexander Drilon4, Michael F. Berger1,2,5, David B. Solit1,4,5, Nikolaus Schultz1,5,6, and Debyani Chakravarty1,2  \nABSTRACT  There is a continuing debate about the proportion of cancer patients that benefit from precision oncology, attributable in part to conflicting views as to which  \nmolecular alterations are clinically actionable. To quantify the expansion of clinical actionability since 2017, we annotated 47,271 solid tumors sequenced with the MSK-IMPACT clinical assay using two temporally distinct versions of the OncoKB knowledge base deployed 5 years apart. Between 2017 and 2022, we observed an increase from 8.9% to 31.6% in the fraction of tumors harboring a standard care (level 1 or 2) predictive biomarker of therapy response and an almost halving of tumors carrying nonactionable drivers (44 .2% to 22 .8%) . In tumors with limited or no clinical actionability, TP53 (43 .2%), KRAS (19.2%), and CDKN2A (12.2%) were the most frequently altered genes.  \nSIGNIFICANCE: Although clear progress has been made in expanding the availability of precision oncologybased treatment paradigms, our results suggest a continued unmet need for innovative therapeutic strategies, particularly for cancers with currently undruggable oncogenic drivers.  \nSee related commentary by Horak and Fröhling, p. 18.  \nINTRODUCTION  \nThe past 25 years have witnessed a dramatic expansion in the number of Food and Drug Administration (FDA) -approved cancer drugs, many of which are primarily or exclusively effective in biomarker-defined populations (1) . This  \n1Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. 2Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 3Department of Computer Science, Yale University, New Haven, Connecticut. 4Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 5Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. 6Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.  \nCurrent address for Ahmet Zehir: Precision Medicine and Biosamples, AstraZeneca, New York, New York; and current address for Jianjiong Gao, Caris Life Sciences, Irving, Texas.  \nexpansion in precision oncology cancer therapies has been driven by large-scale molecular profiling studies, advances in structure-based drug design, and the development of nextgeneration sequencing (NGS)–based diagnostic assays designed to simultaneously identify targetable genomic alterations in  \nCorresponding Author: Debyani Chakravarty, Memorial Sloan Kettering Cancer Center, 323 E 61st St., Room 615, New York, NY 10065. E-mail: [chakravd@mskcc.org](chakravd@mskcc.org)  \nCancer Discov 2024;14:49–65  \ndoi: 10. 1158/2159-8290 . CD-23-0467  \nThis open access article is distributed under the Creative Commons AttributionNonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.©2023The Authors; Published by the American Association for Cancer Research  \nhundreds of cancer-associated genes (2–5). Equally important were innovations in clinical trial design such as basket studies that enabled the rapid testing of novel therapies in biomarkerselected patient cohorts across cancer types. The emergence of biomarker-centric trial design resulted in tumor-agnostic drug (or drug combination) approvals for kinase inhibitors that target TRK/RET fusio","cbCaile2DArHtXrH","https://ap.wps.com/l/cbCaile2DArHtXrH","pdf",9230716,17,"English","# Research Brief\n## Abstract\n## Significance\n## Introduction\n## Background and Context","[{\"question\":\"How did the study quantify changes in clinical actionability from 2017 to 2022?\",\"answer\":\"It annotated 47,271 solid tumors sequenced with the MSK-IMPACT assay using two OncoKB versions deployed five years apart.\"},{\"question\":\"What overall trends were observed in actionable and nonactionable tumors?\",\"answer\":\"The fraction with standard care predictive biomarkers increased from 8.9% to 31.6%, while tumors with nonactionable drivers dropped from 44.2% to 22.8%.\"},{\"question\":\"Which genes were most frequently altered in tumors with limited or no clinical actionability?\",\"answer\":\"TP53 (43.2%), KRAS (19.2%), and CDKN2A (12.2%) were the most frequently altered genes.\"}]","Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer | PDF",1790018897,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/62c1f860943437fa537532f0cd0ad414.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a5106a6fbcf3ee4a89bde95d0f834f02.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6852b69705c75e0bc5f54754594f38f6.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7401e22db23eefd5ae2bd84226e60050.webp",980,1301]